Related references
Note: Only part of the references are listed.Clinical activity of AMG 337, an oral MET kinase inhibitor, in adult patients (pts) with MET-amplified gastroesophageal junction (GEJ), gastric (G), or esophageal (E) cancer.
Eunice Lee Kwak et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The TRIO-013/LOGiC Trial.
J. Randolph Hecht et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Targeting JAK kinase in solid tumors: emerging opportunities and challenges
M. Buchert et al.
ONCOGENE (2016)
INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC)-A study by the Australasian Gastrointestinal Trials Group (AGITG), first results
Nick Pavlakis et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
False-negative rate for HER2 testing in 738 gastric and gastroesophageal junction cancers (GEC) from two global randomized clinical trials
David Cunningham et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer
Yung-Jue Bang et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
S-1 and Cisplatin With or Without Nimotuzumab for Patients With Untreated Unresectable or Metastatic Gastric Cancer A Randomized, Open-Label Phase 2 Trial
Feng Du et al.
MEDICINE (2015)
Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes
Razvan Cristescu et al.
NATURE MEDICINE (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Recurrent Fusion Genes in Gastric Cancer: CLDN18-ARHGAP26 Induces Loss of Epithelelial Integrity
Fei Yao et al.
CELL REPORTS (2015)
Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer
Taroh Satoh et al.
GASTRIC CANCER (2015)
Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study)
Lin Shen et al.
GASTRIC CANCER (2015)
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs
Andrea M. Marquard et al.
BIOMARKER RESEARCH (2015)
Improved survival of gastric cancer with tumour Epstein-Barr virus positivity: an international pooled analysis
M. Constanza Camargo et al.
GUT (2014)
Phosphatidylinositol-3-kinase pathway aberrations in gastric and colorectal cancer: Meta-analysis, co-occurrence and ethnic variation
Mei-Ling Chong et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Body Mass Index and Risk of Second Obesity-Associated Cancers After Colorectal Cancer: A Pooled Analysis of Prospective Cohort Studies
Todd M. Gibson et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Response of blood flow to hyperthermia in human prostate tumors: Opportunities for enhanced radiation effect and drug delivery
Mark Hurwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Prospective, Randomized, Multicenter, Phase III Study of Fluorouracil, Leucovorin, and Irinotecan Versus Epirubicin, Cisplatin, and Capecitabine in Advanced Gastric Adenocarcinoma: A French Intergroup (Federation Francophone de Cancerologie Digestive, Federation Nationale des Centres de Lutte Contre le Cancer, and Groupe Cooperateur Multidisciplinaire en Oncologie) Study
Rosine Guimbaud et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of HER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTANA- A Randomized, Phase III Study
Taroh Satoh et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Is Microsatellite Instability a Prognostic Marker in Gastric Cancer?: A Systematic Review With Meta-Analysis
Yoon Young Choi et al.
JOURNAL OF SURGICAL ONCOLOGY (2014)
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
Charles S. Fuchs et al.
LANCET (2014)
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
Hugo E. R. Ford et al.
LANCET ONCOLOGY (2014)
Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study
Timothy Iveson et al.
LANCET ONCOLOGY (2014)
Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial
Susan J. Dutton et al.
LANCET ONCOLOGY (2014)
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
Hansjochen Wilke et al.
LANCET ONCOLOGY (2014)
Comprehensive molecular characterization of gastric adenocarcinoma
Adam J. Bass et al.
NATURE (2014)
Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma
Miwako Kakiuchi et al.
NATURE GENETICS (2014)
Prognostic Significance of MET Amplification and Expression in Gastric Cancer: A Systematic Review with Meta-Analysis
Zhi Peng et al.
PLOS ONE (2014)
Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers
Johnathan A. Watkins et al.
BREAST CANCER RESEARCH (2014)
The emerging role of MET/HGF inhibitors in oncology
Giorgio V. Scagliotti et al.
CANCER TREATMENT REVIEWS (2013)
Identification of Molecular Subtypes of Gastric Cancer With Different Responses to PI3-Kinase Inhibitors and 5-Fluorouracil
Zhengdeng Lei et al.
GASTROENTEROLOGY (2013)
Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study
Atsushi Ohtsu et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer: Results From a Randomized, Placebo-Controlled, Parallel-Arm, Phase II Trial
Jin Li et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas
Sang Y. Ha et al.
MODERN PATHOLOGY (2013)
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
Tom Waddell et al.
LANCET ONCOLOGY (2013)
Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
Florian Lordick et al.
LANCET ONCOLOGY (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets
Niantao Deng et al.
GUT (2012)
Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone
Jung Hun Kang et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Detection of kinase amplifications in gastric cancer archives using fluorescence in situ hybridization
Shin-ichiro Kiyose et al.
PATHOLOGY INTERNATIONAL (2012)
Molecular Classification of Gastric Cancer: A New Paradigm
Manish A. Shah et al.
CLINICAL CANCER RESEARCH (2011)
Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer - A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
Peter C. Thuss-Patience et al.
EUROPEAN JOURNAL OF CANCER (2011)
Intrinsic Subtypes of Gastric Cancer, Based on Gene Expression Pattern, Predict Survival and Respond Differently to Chemotherapy
Iain Beehuat Tan et al.
GASTROENTEROLOGY (2011)
Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma
Min A. Kim et al.
HISTOPATHOLOGY (2011)
Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
Atsushi Ohtsu et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial
Marc Ychou et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type
Stefano Barbi et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2010)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
Capecitabine and oxaliplatin for advanced esophagogastric cancer
David Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients
Eva Lieto et al.
ANNALS OF SURGICAL ONCOLOGY (2008)
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 study group
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127
Tomislav Dragovich et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer
David Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Relationship between the expression of iNOS,VEGF, tumor angiogenesis and gastric cancer
ZJ Song et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2002)
Share Paper
